Royal Fund Management LLC Acquires Shares of 672 Baxter International Inc (NYSE:BAX)

Royal Fund Management LLC acquired a new stake in shares of Baxter International Inc (NYSE:BAX) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 672 shares of the medical instruments supplier’s stock, valued at approximately $54,000.

Other institutional investors have also recently bought and sold shares of the company. Stifel Financial Corp boosted its position in Baxter International by 66.9% during the 4th quarter. Stifel Financial Corp now owns 1,082,066 shares of the medical instruments supplier’s stock valued at $91,214,000 after acquiring an additional 433,693 shares in the last quarter. Pearl River Capital LLC boosted its position in shares of Baxter International by 316.2% in the 4th quarter. Pearl River Capital LLC now owns 4,162 shares of the medical instruments supplier’s stock worth $348,000 after purchasing an additional 3,162 shares in the last quarter. Delta Asset Management LLC TN boosted its position in shares of Baxter International by 2.3% in the 4th quarter. Delta Asset Management LLC TN now owns 157,437 shares of the medical instruments supplier’s stock worth $13,165,000 after purchasing an additional 3,485 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Baxter International by 1,338.4% in the 4th quarter. Macquarie Group Ltd. now owns 240,918 shares of the medical instruments supplier’s stock worth $20,145,000 after purchasing an additional 224,169 shares in the last quarter. Finally, Creative Planning boosted its position in shares of Baxter International by 5.6% in the 4th quarter. Creative Planning now owns 54,644 shares of the medical instruments supplier’s stock worth $4,569,000 after purchasing an additional 2,922 shares in the last quarter. 83.95% of the stock is currently owned by institutional investors and hedge funds.

Shares of BAX opened at $86.93 on Friday. The firm has a market cap of $43.90 billion, a PE ratio of 26.26, a P/E/G ratio of 2.39 and a beta of 0.84. The company has a current ratio of 2.74, a quick ratio of 2.19 and a debt-to-equity ratio of 0.84. The firm has a fifty day simple moving average of $87.88 and a two-hundred day simple moving average of $85.45. Baxter International Inc has a 1-year low of $69.10 and a 1-year high of $95.19.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.09. The business had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.74 billion. Baxter International had a net margin of 8.85% and a return on equity of 22.70%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.76 EPS. As a group, research analysts forecast that Baxter International Inc will post 3.29 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Friday, June 5th will be paid a dividend of $0.245 per share. The ex-dividend date is Thursday, June 4th. This is a positive change from Baxter International’s previous quarterly dividend of $0.22. This represents a $0.98 dividend on an annualized basis and a yield of 1.13%. Baxter International’s payout ratio is currently 26.59%.

A number of analysts have recently commented on BAX shares. TheStreet raised Baxter International from a “c+” rating to a “b+” rating in a research report on Thursday, April 30th. Citigroup dropped their price target on Baxter International from $94.00 to $89.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 18th. KeyCorp boosted their price target on Baxter International from $92.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Raymond James boosted their price target on Baxter International from $90.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, April 13th. Finally, SVB Leerink boosted their price objective on shares of Baxter International from $96.00 to $105.00 and gave the stock an “outperform” rating in a report on Friday, May 1st. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $95.90.

In related news, SVP Sean Martin acquired 9,780 shares of Baxter International stock in a transaction dated Monday, March 30th. The stock was purchased at an average cost of $82.19 per share, for a total transaction of $803,818.20. Following the purchase, the senior vice president now directly owns 39,504 shares of the company’s stock, valued at approximately $3,246,833.76. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jeanne K. Mason sold 47,146 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $93.13, for a total value of $4,390,706.98. Following the completion of the sale, the senior vice president now owns 163,485 shares of the company’s stock, valued at $15,225,358.05. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.